Sort
15,842 grants matching “pancreatic cancer”
Core C: Computational Core
$212,725Phillip Andrew Futreal · University Of Tx Md Anderson Can Ctr · P01 · FY2019 · CA
Effects of salinomycin and binding target proteins in pancreatic cancer
$212,721Erxi Wu · North Dakota State University · P20 · FY2017 · GM
IDO-silencing Salmonella therapy for the treatment of primary and metastatic PDAC
$212,663Don J Diamond · Beckman Research Institute/City Of Hope · R21 · FY2014 · CA
Genetic Pathways Governing Pancreatic Ductal Adenocarcinoma
$212,639Ronald Anthony Depinho · Dana-Farber Cancer Inst · P01 · FY2007 · CA
MRI-guided Ultrasonic Ablation of Pancreatic Cancer
$212,620Frank Graham Sommer · Stanford University · R21 · FY2010 · CA
Project 3: Combination inhibition of ERK for pancreatic cancer treatment
$212,596Andrea Wang-Gillam · Washington University · P50 · FY2020 · CA
Somatic Engineering-based Models of Pancreatic Cancer
$212,580Monte Meier Winslow · Stanford University · R21 · FY2015 · CA
Mutation-Specific p53 Antibodies as Biomarkers of Pancreatic Cancer
$212,556Karen Sue Anderson · Arizona State University-Tempe Campus · R21 · FY2012 · CA
Core C: In vivo Imaging, Dosimetry and Sensing of Photodynamic-Immune Responses and Synergies
$212,555Brian William Pogue · Massachusetts General Hospital · P01 · FY2023 · CA
Single molecule microarrays for the detection of mutant DNA in body fluids
$212,371Alfredo Andres Celedon · Scanogen, Inc. · R21 · FY2014 · CA
Mutant p53 gain-of-function as an actionable target in cancer therapy
$212,358Alice Nemajerova · State University New York Stony Brook · R50 · FY2022 · CA
Mutant p53 gain-of-function as an actionable target in cancer therapy
$212,358Alice Nemajerova · State University New York Stony Brook · R50 · FY2021 · CA
Mutant p53 gain-of-function as an actionable target in cancer therapy
$212,358Alice Nemajerova · State University New York Stony Brook · R50 · FY2020 · CA
Molecular Mechanisms Controlling Endocytic Recycling
$212,273Steven H Caplan · University Of Nebraska Medical Center · R01 · FY2009 · GM
PKD1 signaling in the initiation of pancreatic cancer
$212,223Peter Storz · Mayo Clinic Jacksonville · R01 · FY2018 · CA
A dual histone deacetylase and glycogen synthase kinase 3 beta inhibitor for treating pancreatic adenocarcinoma
$212,201Mouad Edderkaoui · Avenzoar Pharmaceuticals, Inc. · R41 · FY2019 · CA
GENETIC RADIOIMMUNOTHERAPY OF PANCREATIC CANCER
$212,160University Of Alabama At Birmingham · R01 · FY2000 · CA
X-ray studies of metalloenzyme regulation and catalysis
$212,131Catherine L Drennan · Massachusetts Institute Of Technology · R01 · FY2008 · GM
Experimentally Validated Mathematical Modeling of Oncolytic Virus Infection
$211,977Wolfgang Michael Korn · University Of California, San Francisco · R01 · FY2009 · CA
Experimentally Validated Mathematical Modeling of Oncolytic Virus Infection
$211,977Wolfgang Michael Korn · University Of California, San Francisco · R01 · FY2008 · CA
Core B: Organoid Biobank
$211,931Camila Dos Santos · Cold Spring Harbor Laboratory · P01 · FY2024 · CA
Identification and characterization of interaction atlases in human
$211,929Hasan Otu · University Of Nebraska Lincoln · R21 · FY2019 · LM
A New Anti-CD27 Monoclonal Antibody Adjuvant for Pancreatic Cancer Vaccines
$211,875Bei Wang · Rockefeller University · R21 · FY2012 · AI
Breakdown of Desmoplasia in Pancreatic Cancer to Enhance Drug Effectiveness
$211,859Yves Boucher · Massachusetts General Hospital · R21 · FY2014 · CA
Exploiting Lineage-Specific Dependencies in Solid Tumors: Using Transcription Factors to Drive Therapeutic Effect In Situ
$211,778John M. Wrangle · Medical University Of South Carolina · R21 · FY2024 · CA